Please ensure Javascript is enabled for purposes of website accessibility

My Favorite Biotech Stock Right Now

By Taylor Carmichael - Jun 27, 2021 at 12:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

I'm an owner of Schrodinger because this company's software is revolutionizing drug discovery, and it's going to be a monster stock over the next decade.

Veeva Systems (VEEV -0.32%) has proven how valuable software can be in organizing clinical trial data. Schrodinger's (SDGR -0.17%) solution is even more vital, in my opinion, as it's helping drug companies navigate drug discovery. Schrodinger helps big pharma find the right molecule for the right target, and it helps them do it a lot quicker than normal human research.

In this clip from Fool Live, Corinne Cardina, the bureau chief of healthcare and cannabis at Fool.com, and Motley Fool writer Taylor Carmichael discuss why Schrodinger is his favorite biotech stock right now. This segment was recorded on June 18.

 

Corinne Cardina: Taylor, we have two more minutes so let me give you this space to do a quick elevator pitch on your favorite healthcare stock to buy right now. What is it?

Taylor Carmichael: My favorite one right now is Schrodinger. See if I can get their ticker right from my memory, SDGR, Schrodinger. Schrodinger's a tech stock, but they're a tech stock for the healthcare industry. So it's very similar in that regard to Veeva Systems, which has been a terrific stock for Foolish investors. Veeva Systems has a $47 billion market cap. Veeva specializes in organizing all that data in clinical trials. Well, Schrodinger is way before that process. Schrodinger's technology helps pharmaceutical companies find the best molecule, find the best drug at the research stage before you have to trial it in human beings. Their computers -- and its AI combined with computational physics -- their computers can run through millions of potential targets, millions of potential molecules, and just run, run, run through that data super quickly and get the best possible molecule for pharmaceutical companies. Twenty of the top 20 big pharma all use Schrodinger's solution. Bill Gates owns 11% of the company. It's a $5 billion company. I think -- I'm looking at Veeva saying, "Well, they can be at least as big as Veeva," -- so a nine-bagger. They're also eating their own cooking. They are creating their own molecules, they own the rights to, and they're going to start clinical trials. It's a 2-in-1 stock, you get the tech side, you also get a promising biotech company. Very excited about Schrodinger.

Cardina: If you like Veeva, you'll probably like Schrodinger. I love it. I own one share of Veeva. I think I would like to extend my AI and healthcare play by adding Schrodinger in the near term. I'm one share of everything, I'm very diversified. [laughs]

Corinne Cardina owns shares of Veeva Systems. Taylor Carmichael owns shares of Schrödinger, Inc. The Motley Fool owns shares of and recommends Schrödinger, Inc. and Veeva Systems. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Schrödinger, Inc. Stock Quote
Schrödinger, Inc.
SDGR
$28.55 (-0.17%) $0.05
Veeva Systems Inc. Stock Quote
Veeva Systems Inc.
VEEV
$224.40 (-0.32%) $0.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.